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Abstract 
Placental amino acid transfer is essential for fetal development and its impairment is associated with poor 
fetal growth. Amino acid transfer is mediated by a broad array of specific plasma membrane transporters 
with overlapping substrate specificity. However, it is not fully understood how these different transporters 
work together to mediate net flux across the placenta. Therefore the aim of this study was to develop a 
new computational model to describe how human placental amino acid transfer functions as an 
integrated system. Amino acid transfer from mother to fetus requires transport across the two plasma 
membranes of the placental syncytiotrophoblast, each of which contains a distinct complement of 
transporter proteins. A compartmental modelling approach was combined with a carrier based modelling 
framework to represent the kinetics of the individual accumulative, exchange and facilitative classes of 
transporters on each plasma membrane. The model successfully captured the principal features of 
transplacental transfer. Modelling results clearly demonstrate how modulating transporter activity and 
conditions such as phenylketonuria, can increase the transfer of certain groups of amino acids, but that 
this comes at the cost of decreasing the transfer of others, which has implications for developing clinical 
treatment options in the placenta and other transporting epithelia.  
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1. Introduction 
The placenta is the interface between the maternal and fetal circulations and plays an essential 
role in mediating the transfer of all the nutrients required for fetal development, including amino 
acids. Impaired placental transfer of amino acids during pregnancy is associated with poor fetal 
growth, which increases the risk of poor pregnancy outcomes such as stillbirth (1) and of chronic 
disease in adult life (2-4). There are currently no effective treatments for fetal growth restriction 
(FGR) and a better understanding of placental transfer as a whole could potentially contribute to 
the development of treatment strategies for intervention and prevention of the disease.  
Transfer of amino acids across the placenta is a complex process, influenced by multiple 
factors including placental blood flow, membrane transporters, intracellular metabolism and 
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placental morphology (5, 6). In order to pass from the maternal intervillous space into the fetal 
capillaries, amino acids need to cross the placental syncytiotrophoblast, an epithelial barrier 
separating the two circulations. Amino acids in the maternal blood first need to be transported 
across the microvillous plasma membrane (MVM) of the placental syncytiotrophoblast into the 
cytosol. They can then either undergo metabolism or can be transported across the fetal-facing 
basal plasma membrane (BM), from where it is assumed they diffuse across the fetal capillary 
endothelium to the fetal circulation [6]. 
Amino acid transport across the MVM and BM is mediated by specific transport proteins 
(6), which operate using different energetically passive and active transport mechanisms. 
Accumulative transporters actively pump amino acids into the placental syncytiotrophoblast 
against their concentration gradient, using secondary active transport driven by the sodium 
electrochemical gradient. This serves as an important driving force for amino acid transfer as a 
whole, since fetal amino acid concentrations are higher than maternal concentrations (7) and 
syncytiotrophoblast cytosol concentrations are higher than both (8). Exchangers (antiporters) are 
another important class of transporter, which take one amino acid from outside of the plasma 
membrane and swap it for another amino acid from inside the syncytiotrophoblast. Thus, 
exchangers mediate changes in the relative amino acid composition but not the overall net 
amount. Facilitative transporters on the other hand are responsible for mediating net transport 
to the fetus, via facilitative diffusion driven by the amino acid electrochemical gradients (9, 10).  
Critically, these three classes of transporter need to work together to mediate net 
transfer of all the required amino acids to the fetus, as it is not possible for one to do so alone (9, 
11). For example, substrates taken up by the accumulative transporter across the MVM can be 
exchanged back to the mother to drive uptake by exchangers of amino acids that are not 
substrates of the accumulative transporter. Similarly, the exchangers at the BM transfer amino 
acids to the fetus that are not substrates of the facilitative transporters.  
While many studies of amino acid transfer have focussed on individual transporters, the 
integrated study of the interactions between multiple transporters in the two placental plasma 
membranes has been limited (9, 12). There are twenty amino acids, which can either inhibit or 
promote each other’s transport, and many distinct transporter proteins with overlapping 
substrate specificity. Hence, given this inherent complexity, a systems approach using 
mathematical modelling is necessary to help describe the transport process as a whole. Previous 
placental models have mainly focussed on blood flow and oxygen transport by simple diffusion, 
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which has proved highly valuable to explain placental structure-function relationships (13-17), 
while models for membrane transport have been applied for the placental transfer of drugs (18) 
and glucose (19). We have previously introduced a model of human placental amino acid 
transfer, applied to the uptake and exchange of serine and alanine (20). However, a systematic 
integrated analysis of amino acid transfer is required, including more mechanistic transporter 
models (6, 21, 22).  
The aim of this study was to develop a modelling framework for human placental amino 
acid transfer as an integrated system, to better understand (i) how different types of transporter 
work together, (ii) how composition of amino acids affects transport, and (iii) how specific 
transporter activities can drive net transfer of all amino acids to the fetus.  
 
2. Methods 
2.1 Compartmental model for the placenta 
A compartmental modelling approach was adopted based on our previous work (20), in which 
the placenta was represented as three separate volumes, corresponding to the maternal 
intervillous space, syncytiotrophoblast, and fetal capillaries respectively (Fig. 1). All 
compartments were assumed to be well mixed, as the main focus is on the transporter 
interactions. The transfer of amino acids between compartments was modelled as fluxes 
mediated by the various types of transporters (9). In each membrane (MVM and BM), transport 
by a certain type of transporter was combined and modelled as a single representative 
transporter. At the maternal-facing MVM these included transport by an accumulative and an 
exchange transporter, while at the fetal- facing BM transport by a facilitative and an exchange 
transporter (Fig. 1). Note that accumulative transporters are also found on the BM, but these 
were not included in the model as their role is thought to be limited (11). Details of the model 
implementation are described below. 
 The rate of change in the concentration of a certain amino acid A within each 
placental compartment is given by:  
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where [A]i is the concentration (mol l-1) of substrate A in compartment i, and    is the 
compartment volume (l).   
   
 represent the net molecular flux (mol min-1) of A from 
compartment i to j. Here m, s, and f, are the maternal, syncytiotrophoblast and fetal 
compartments respectively, while ac, ex, and fa denote the accumulative, exchange, and 
facilitative transporters.        
  is the net molecular flux (mol min-1) due to blood flow. 
 
 
Fig. 1: Compartmental model of the placental amino acid transfer system, representing the volumes of the maternal 
intervillous space (  ), placental syncytiotrophoblast (  ), and fetal capillaries (  ). Amino acid transporters 
included at the maternal-facing microvillous membrane (MVM) were accumulative transporter (Ac) and exchanger 
(Ex), and those at the fetal-facing basal membrane (BM) were facilitative transporter (F) and exchanger (Ex).    and 
   are the flow inputs (and outputs) in the maternal and fetal compartments respectively.     and     indicate 
amino acid concentrations in the various compartments. 
 
2.2 Classification of amino acids in representative groups 
Amino acids were categorised according to their transporter specificity into four generic groups, 
to reduce complexity in the first instance. As shown in Table 1, these representative amino acid 
groups were AcEx, substrate of the accumulative and exchange transporters; Ex, exchange only 
substrate; ExF, substrate of exchange and facilitative transporters; and AcExF, substrate of all 
transporter types. Normal physiological concentrations of amino acids (7, 8) were summed per 
representative group in each compartment. Glutamate and aspartate were not included in the 
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model as these are taken up by distinct transport systems (EAATs) and their interactions with the 
transfer of other amino acids would be extremely limited. 
 
Table 1: Amino acids groups distinguished in the model as categorised by transporter specificity and their 
physiological concentrations (7, 8)
*
. 
Amino 
acid 
group 
Transporter 
specificity 
Name Maternal  
concentration 
(µmol l
-1
) (7) 
Syncytiotrophoblast 
concentration  
(µmol l
-1
) (8) 
 
Umbilical 
artery 
concentration 
(µmol l
-1
) (7) 
Umbilical vein 
concentration 
(µmol l
-1
) (7) 
 
AcEx Accumulative 
and Exchange 
Arginine 51 320 101 108 
  Glutamine 368 1135 482 494 
  Glycine 107 1655 217 218 
  Histidine 85 74 108 119 
  Lysine 131 508 317 343 
  Serine 84 721 144 142 
  sum  826 4413 1369 1424 
Ex Exchange Threonine 170 786 258 270 
ExF Exchange and  
Facilitative 
Isoleucine 43 105 56 63 
  Leucine 81 305 105 120 
  Phenylalanine 39 173 63 65 
  Tyrosine 34 220 59 59 
  Valine 141 342 200 216 
  sum  338 1145 483 523 
AcExF Accumulative, 
Exchange, and 
Facilitative 
Alanine 215 1987 238 282  
* Note, glutamate and aspartate were excluded as these are taken up by distinct transport systems. Asparagine, 
proline and methionine were not included as the data sets used did not contain values for all three compartments. 
 
 
 
2.3 Individual transporter models 
Models for each type of transporter were developed based on the principles of carrier-mediated 
transport (21, 23), to represent the simultaneous transport of multiple substrates. Briefly, 
parameters describing the kinetic properties were kept to the minimum required to represent 
the functional activity of each transporter type. Therefore, in the first instance, exchanger and 
facilitative transporter translocation rate constants were assumed to be symmetric and binding 
affinities equal on both sides of the plasma membrane. In addition, substrates of a certain type 
of transporter were all assumed to have identical kinetic and binding properties.  
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Exchanger model 
For the exchanger with multiple substrates, the net flux of substrate A from compartment I to II 
(mol min-1) is given by (24): 
  
     
        
                   
                                   
 (Eq. 4) 
 
where [A]i is the concentration of substrate A (mol l-1) in compartment I or II,  [Tot]i is the total 
sum of all exchanger substrates, while [R]i denotes the sum of all exchanger substrates, but 
excluding substrate A in compartment i. Kex is the dissociation constant (mol l
-1), assumed equal 
for all substrates of the exchanger, and Vex is the maximum transport rate (mol min
-1). 
 
Facilitative transporter model  
For the facilitative transporter with multiple substrates, the net flux of substrate A from 
compartment I to II (mol min-1) is given by (24): 
 
     
        (
    
          
 
     
           
) (Eq. 5) 
 
where [A]i is concentration of substrate A (mol l-1) in compartment i,  [Tot]i is the sum of the 
concentrations of all substrates of the facilitative transporter in compartment i. Kfa is the 
dissociation constant (mol l-1), assumed equal for all substrates of the facilitative transporter, 
and Vfa is the maximum transport rate (mol min
-1). 
 
Accumulative transporter model 
Accumulative transporters operate via secondary active transport driven by the sodium 
electrochemical gradient. A cotransport model was adopted (24), in which it was assumed that 
sodium binds to the transporter first, followed by the amino acid (25) and that only the 
translocation of the carrier-sodium-substrate complex was electrogenic. The net flux of substrate 
A from compartment I to II (mol min-1) is given below for the model distinguishing two different 
substrates: 
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where [A]i and [B]i are the concentrations (mol l-1) of substrate A and B in compartment i, [Tot]i is 
the sum of substrates A and B. Kac and KNa represent the dissociation constants (mol l
-1) of the 
amino acid substrates and sodium, respectively, and Vac is the transport rate constant (mol min
-1). 
The electrical potential induced bias was given by ε’ and ε for the forward and backward 
transport rate, respectively (26).   represents the electrical bias constant, z is the charge of 
sodium, F is the Faraday constant, R is the gas constant, T is the absolute temperature and ∆Ψ is 
the membrane potential difference between side I and II (Table 2).  
 
2.4 Compartmental blood flow  
Blood flow in and out of the maternal and fetal compartments was modelled as constant (non-
pulsatile). Compartments were assumed well mixed, with flow resulting in a net molecular flux 
(mol min-1) as follows:  
 
       
    (     
      ) (Eq. 7) 
 
where [A]iin is the input concentration (mol l
-1) of substrate A in compartment i and [A]i is the 
concentration in the compartment.    is the flow rate in and out of compartment i (l min
-1).  
 
2.5 Model parameters  
Reference parameters are reported in Table 2. In general, the parameters selected were for 
normal physiological conditions. A single functional unit of the placenta (cotyledon) was 
modelled with a volume of 30 ml (~30 g), as described previously (20, 27). For the transporter 
models, the transport rate constants   were initially taken equal for each class of transporter to 
clearly evaluate their influence on the system (20).  
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Table 2: Reference parameter values.  
Parameter Value Unit Reference 
Compartmental model:    
Total placental cotyledon volume 30 ml (10, 20) 
% maternal volume (intervillous space) 34% -  (20, 27) 
% syncytiotrophoblast volume    15% -  (20, 27) 
% fetal volume (fetal capillaries) 7.5% - (20, 27) 
Maternal blood flow rate 2 ml min
-1
 g
-1
 (28) 
Fetal blood flow rate 0.2 ml min
-1
 g
-1
 (29) 
    
Transporter models:    
Accumulative     
Effective transport rate, Vac 0.005 mmol min
-1
 (20) 
Charge of sodium ion, z 1  - - 
Faraday Constant, F 9.65 x 10
4
 C mol
-1
 - 
Gas Constant, R 8.314 VC K
-1
 mol
-1
 - 
Body temperature, T 310 K - 
Transmembrane potential difference, ∆Ψ -21 mV  (30) 
Maternal sodium concentration 134 mmol l
-1
 (31)
a
 
Syncytiotrophoblast sodium concentration 15 mmol l
-1
 (32)
b
 
Electrical bias constant,   0.33 - (33)c 
Substrate dissociation constant, Kac  2.26 mmol l
-1
 (33)
c
 
Sodium dissociation constant, KNa  25.07 mmol l
-1
 (33)
c
 
MVM Exchanger    
Maximum transport rate, Vex,mvm 0.005 mmol min
-1
 (20) 
Substrate dissociation constant, Kex  200 µmol l
-1
 (34, 35)
d
  
BM Exchanger    
Maximum transport rate, Vex,bm 0.005 mmol min
-1
 (20) 
Substrate dissociation constant, Kex  200 µmol l
-1
 (34, 35)
d
  
Facilitative    
Maximum transport rate, Vf 0.005 mmol min
-1
 (20) 
Substrate dissociation constant, Kf  1000 µmol l
-1
 (36)
d
 
a
 Mean of lower and upper late pregnancy values. 
b
 Intracellular value for brain as no specific information available. 
c
 
Fitted based on data Yao et al., Fig. 5f (24, 33). 
d
 Representative value based on weighted average dissociation 
constants. 
 
2.6 Numerical implementation  
All models were implemented in Matlab (R2014a). To predict the concentrations of amino acids 
in each compartment, time integration of Eq. 1-3 was performed using the ode45 function 
(Runge-Kutta (4, 5) method). Sensitivity analyses for the different model parameters were 
carried out based on steady state values of fetal amino acid transfer. 
 
2.7 Parameter estimation 
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The effective transport rate parameters for each transporter included in the model (   ,      , 
      , and   ) were fitted simultaneously based on the relative (normalised) error between the 
literature and predicted steady state fetal venous-arterial concentration difference. A least 
square criterion was used with all amino acid groups weighted equally.  The fitting procedure 
was implemented using the fminsearch function in Matlab (Nelder-Mead method). 
 
3. Results 
This section will first explore how amino acids are transferred to the fetus across each 
syncytiotrophoblast plasma membrane (MVM and BM) separately. Subsequently, MVM and BM 
are combined, producing an integrated representation of how amino acids cross the placenta. 
Sensitivity analyses for model parameters are presented to understand the transport system as a 
whole and how these affect the different amino acid groups. Lastly, an example of the impact of 
a certain genetic condition with elevated phenylalanine levels (maternal phenylketonuria) is 
explored using the model. 
 
3.1 Uptake of maternal amino acids: transport interactions across the microvillous 
plasma membrane 
Transport of amino acids across the MVM is mediated by both accumulative and exchange 
transporters (Fig. 1). While the accumulative transporters actively pump amino acids into the 
syncytiotrophoblast, the exchangers are responsible for equalising their relative composition. 
The amino acid substrates from Table 1 were categorised further into two groups according to 
their transporter specificity at the MVM: 1) Accumulative and exchange transporter substrate, 
MVMAcEx, consisting of AcEx and AcExF, and 2) Exchanger-only substrate, MVMEx, consisting of 
Ex and ExF. Physiological amino acid concentrations (Table 1) were combined and used as initial 
values for the maternal and syncytiotrophoblast compartments respectively and as constant 
input concentrations into the maternal compartment. Initially, transport across the BM was 
disabled to clearly demonstrate the potential for uptake across the MVM. The model showed 
concentrations in the syncytiotrophoblast rising well above maternal concentrations for both 
MVMAcEx and MVMEx (Fig. 2). This demonstrated that the combined accumulative and 
exchange transporter configuration allowed uptake of both amino acid groups across the MVM 
by transporting intracellular MVMAcEx substrates back out again from the syncytiotrophoblast in 
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exchange for external MVMEx substrates. The syncytiotrophoblast concentrations of both 
substrate groups rose well above physiological values; however it is important to note that in 
this case the model only considered the MVM transporter activities and did not include efflux 
transport across the BM, which would lead to a lower equilibrium. Steady state concentrations 
were reached when the opposing gradients in accumulative transporter substrate and sodium 
electrochemical potential were equilibrated and the fraction of exchanger substrates equalised 
in both compartments. Thus, changes in transporter activity did not affect the equilibrium 
syncytiotrophoblast concentrations, but only the uptake rate and thus the speed at which this 
equilibrium was reached. This can be observed for the accumulative transporter activity in Fig. 2. 
In principle, higher exchanger activity could promote exchange of MVMAcEx back to the 
maternal side, leading to slower accumulation of MVMAcEx amino acids and faster uptake of 
MVMEx into the syncytiotrophoblast. However, increasing the exchanger activity by a factor 10 
only had a minor impact, as the relative composition of both compartments already appeared to 
be in quasi steady equilibrium at any moment in time (results not shown). 
 
Fig. 2: Model simulations of transport interactions at the MVM using physiological concentrations (Table 1). MVMEx 
consists of the sum of all amino acids transported by exchange only at the MVM, while MVMAcEx consists of the 
sum of those transported by exchange as well as accumulative transporters. Solid lines:  equal accumulative and 
exchange transporter activities. Dashed lines: 10x increased accumulative transport activity. Note this does not 
affect equilibrium concentrations. Online version in colour. 
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3.2 Fetal delivery of amino acids: transport interactions across the basal plasma 
membrane 
Exchange and facilitative transporters localised to the BM are responsible for the delivery of 
amino acids to the fetus. While exchangers are important in regulating the relative composition 
of amino acids, it is the BM facilitative transporters which mediate net delivery of amino acids to 
the fetus. Thus, the interactions between these transporters were explored in Fig. 3. The amino 
acid concentrations from Table 1 were grouped further according to their transporter specificity 
at the BM: 1) Exchange substrates alone, BMEx, consisting of groups AcEx and Ex, and 2) 
Exchange and facilitative substrates, BMExF including ExF and AcExF. The combined umbilical 
arterial concentrations were used as both initial values and input concentrations for the fetal 
compartment, while in this case the syncytiotrophoblast amino acid concentrations were kept 
constant throughout the simulations. The results in Fig. 3 show an increase in fetal delivery for 
BMExF, evident from the increase in umbilical vein concentration over time. In contrast, a slight 
decrease in the fetal concentration of BMEx was observed, which implies reverse transport into 
the syncytiotrophoblast. This was due to the higher input fraction of BMEx in the fetal 
compartment (0.69) than the fraction in the syncytiotrophoblast (0.62), which led to reverse net 
transport due to exchange. However, it was shown that increasing the facilitative activity (e.g. by 
10 fold) can indirectly boost the fetal delivery of BMEx to the fetus (Fig. 3). This is because the 
increased efflux of BMExF by the facilitative transporter reduced the fraction of BMEx in the fetal 
compartment, and once this fraction was lower than the fraction in the syncytiotrophoblast this 
then enabled net transfer to the fetus by the exchanger. However, lowering the fraction of BMEx 
in this way required a substantial increase in fetal compartment BMExF to a concentration much 
higher than physiological in the umbilical vein. 
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Fig. 3: Model simulations of transport interactions at the BM using physiological concentrations (Table 1). BMEx is 
the sum of all substrates transported by exchange only at the BM, while BMExF is the sum of all substrates 
transported by both exchangers and facilitated transporters. Note that in the model the fetal compartment 
concentration equals that in the umbilical vein. Solid lines: equal exchanger and facilitative transporter activity. 
Dashed lines: 10x increased facilitative transport activity. For equal activity, the steady state level of BMEx at the 
end was slightly lower than the initial and input concentration, implying reverse transport from the fetal 
compartment into the syncytiotrophoblast. 
 
3.3 Transfer across the placenta from mother to fetus 
Having separately established the mechanisms of transport at the BM and MVM, the next step 
was to consider both membranes simultaneously. All three placental compartments were 
included (Fig. 1) and model simulations of the four groups of amino acids were generated using 
the physiological concentrations from Table 1 as inputs and initial conditions. The model 
simulations in Fig. 4 demonstrated that all four amino acid groups were successfully transferred 
to the fetal compartment, as evident from a net increase in their umbilical vein concentrations. 
Using literature values for maternal and fetal plasma as well as intracellular concentrations, the 
model appeared to be operating near steady state, although the amino acid groups AcEx and in 
particular AcExF showed reductions from the initial concentrations in the syncytiotrophoblast. 
Simulated results at steady state were compared with the umbilical venous-arterial 
concentration difference from literature (7) and appeared to correspond reasonably well on first 
inspection (Table 3), without any tuning of the model parameters. However, the model over-
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predicted transfer for amino acid groups AcExF and ExF to various degrees and under-predicted 
AcEx and Ex, with the greatest relative discrepancy being for Ex. 
 
 
Fig. 4: Model simulation of amino acid transfer across the placenta, showing the amino acid concentrations of the 
different groups of amino acids in each of the placental compartments. Simulations using physiological amino acid 
concentrations (Table 1) and model parameters from Table 2. Results represent the sum of all amino acids in each 
group. Note fetal AcExF rises sharply initially before going down again. Results demonstrated positive fetal delivery 
for all amino acids at steady state. 
 
 
Table 3: Umbilical venous-arterial concentration differences for each amino acid group.  
Amino acid  
group 
Reference simulation 
(µmol l
-1
) 
Literature (7)  
(µmol l
-1
) 
Model fit 
(µmol l
-1
) 
AcEx    46 55 53 
Ex 2.7 12 9.3 
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ExF 43.6 40 32.5 
AcExF 67.4 44 70 
 
3.4 Effects of individual transporter activities 
The effect of varying the relative activity of each transporter type was explored. Reference 
transport activity parameters   for the accumulative, MVM exchange, BM exchange, and 
facilitative transporter (Table 2) were varied. Increasing the activities of accumulative and 
facilitative transporters promoted the placental transfer of all amino acid groups (Fig. 5a and d), 
until limits in placental transfer were reached. Interestingly, the results also showed that while 
increasing the activity of particular transporters promoted the transfer of certain amino acids, 
this was detrimental to the transfer of others. For example, increasing BM exchanger activity 
would result in a decrease in fetal delivery of amino acids that are transported by facilitative 
transporters (ExF and AcExF) (Fig. 5c), since this promotes exchange back into the 
syncytiotrophoblast. Similarly, increasing MVM exchanger activity promoted uptake and fetal 
delivery of those amino acids that are transported by exchange only at the MVM (Ex and ExF) at 
the expense of AcEx (Fig. 5b), which is taken up by the accumulative transporter and exchanged 
back into the maternal compartment. However, surprisingly an increase in placental transfer was 
observed for AcExF (Fig. 5b), which has the same accumulative-exchange transporter specificity 
at the MVM as AcEx. This is because in the reference simulation the syncytiotrophoblast fraction 
of AcExF dropped from a high initial ratio of 0.24 down to 0.11 at steady state, which is lower 
than the ratio of 0.14 on the maternal side. Increasing MVM exchange activity would then 
promote AcExF uptake into the syncytiotrophoblast compartment and in turn increase transfer 
to the fetal compartment by facilitated transport. Thus, MVM exchangers affected BM transfer 
indirectly, and in opposite manners depending on how the overall transport system shifted the 
concentration ratios of each amino acid in the three compartments. Lastly, it can be noted from 
Fig. 5a-d that the placental transfer of amino acid Ex (transported by exchanger only) could be 
driven by increasing any transporter activity, but only to a small degree. Negative fetal delivery, 
corresponding to amino acid transport out of the fetal compartment into the 
syncytiotrophoblast can occur for AcEx at very low facilitated (Fig. 5d) or accumulative (Fig. 5a) 
transporter activity. 
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Fig. 5: Individual transporter activity sensitivity analysis. Fetal venous-arterial difference at steady state for each 
amino acid group in response to variations in individual transporter activity with respect to the reference 
parameters (Table 2). Results represent the sum of all amino acids in each group. 
 
3.5 Interactions between multiple transporter activities 
A series of simulations was performed in which two transporter activities were varied 
simultaneously to explore their interactions. First, the overall impact of exchanger activity on net 
placental transfer of each amino acid was explored by varying both MVM and BM exchanger 
activities (Fig. 6). This showed that for amino acid AcEx, increasing exchange activity at the BM 
while reducing exchange activity at the MVM would result in optimal fetal delivery (i.e. by 
promoting exchange to the fetus, while reducing back exchange to the maternal compartment). 
In contrast, for ExF and AcExF, both of which are facilitative substrates, increasing BM exchange 
activity could lead to reuptake into the syncytiotrophoblast. Interestingly, for AcExF, the BM 
exchanger activity had opposite effects on net transfer depending on whether the MVM 
exchanger activity was high or low. It was shown that in addition to having both exchanger 
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activities high, additional high AcExF transfer could occur when both activities were low. This is 
because for low exchange activities the accumulative and facilitative transporters would 
dominate transfer, while back-exchange into the maternal and syncytiotrophoblast 
compartments is limited. For Ex, higher fetal uptake can be achieved by increasing both 
exchange activities, however, the overall transfer remained relatively small. 
 
Fig. 6: Effects of exchanger activity. Fetal venous-arterial difference at steady state for each amino acid group when 
the exchanger activities at the MVM and BM were varied simultaneously. 
  
 Next it was investigated how overall transport is affected by the transporters on the 
MVM, by simultaneously varying the accumulative and MVM exchange activities (Fig. 7). The 
results showed that maximum placental transfer of AcEx and AcExF occurred when the 
accumulative activity is high, which promotes uptake into the syncytiotrophoblast, and the 
exchange activity is low, which limits back-exchange. For Ex and ExF, the maximum delivery in 
the fetal compartment was achieved when both transporter activities at the MVM were high. 
This is because both transporters promote uptake via exchange into syncytiotrophoblast for 
these substrates, either directly or indirectly by increasing the intracellular concentrations of the 
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driving substrates. Note that negative fetal delivery (transport out of the fetal compartment into 
the syncytiotrophoblast) occurred under certain conditions; for instance, for AcEx when the 
accumulative activity is low. This occurred because low MVM uptake of AcEx meant that its ratio 
in the syncytiotrophoblast was lower than on the fetal side, leading to reverse transport by BM 
exchange.  
 
Fig. 7: Effects of transporter activity at the MVM. Fetal venous-arterial difference at steady state for each amino acid 
group when varying the MVM exchanger and accumulative transporter activities simultaneously. 
 
 The impact of the transporter activities in the BM was evaluated by varying the 
activities of the BM exchanger and facilitative transporters (Fig. 8). The model suggested that for 
ExF and AcExF, the fetal delivery was optimal when the facilitative activity was high and the 
exchange activity at the BM was low. This combination promoted transfer to the fetus, while at 
the same time limiting reuptake. Additionally, it was shown that for AcEx and Ex, which are not 
substrates of the facilitative transporter, the fetal delivery was increased when all transport 
activities were high at the BM. These substrates must be exchanged to transfer across the BM, 
therefore promoting exchange will directly increase their transfer, and this is promoted 
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indirectly by increasing the facilitative activity, since this leads to a more favourable exchange 
ratio.  
 
Fig. 8: Effects of transporter activity at the BM. Fetal venous-arterial difference at steady state for each amino acid 
group when varying the BM exchanger and facilitative transporter activities simultaneously. 
 
3.6 Flow sensitivity  
The impact of maternal and fetal blood flow on placental transfer was analysed for each amino 
acid group. Flow rates were only found to be rate limiting when either maternal or fetal flow 
approached zero. The system appeared to be most sensitive to changes in the fetal flow due to 
its small volume fraction (Fig. 9). In contrast, the maternal flow did not appear to significantly 
affect fetal delivery. The model suggested that a slow fetal flow rate translated to high fetal 
delivery for AcEx and Ex (not facilitative substrates), while faster fetal flow rate would stimulate 
fetal delivery of ExF and AcExF (facilitative substrates). This is because for the facilitative 
substrates, high fetal flow maintains the BM concentration gradients driving facilitated transport. 
While for amino acids that cannot be transported by facilitative transporters, high fetal flow 
would maintain the less favourable influx concentration ratios, which determine transport by the 
exchangers.  
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Fig. 9: Flow sensitivity analysis. Net transfer to the fetus for each amino acid group in response to varying the 
maternal and fetal flow inputs simultaneously. 
 
3.7 Model sensitivity to amino acid input concentrations 
The initial amino acid levels and input concentrations in the maternal and fetal compartments 
were varied using the same factor for all four amino acid groups with respect to their reference 
concentrations in Table 1. The results in Fig. 10 demonstrated that low fetal amino acid levels 
and high maternal amino acid levels generally promoted fetal transport, as would be expected. 
In addition, maternal amino acids became limiting only at low levels. The results also showed 
that negative net transfer could occur when maternal concentrations are extremely low and fetal 
concentrations are high.  
0
1
2
0
1
2
0
100
200
300
Fetal flow 
(fold change)
AcEx
Maternal flow 
(fold change)
F
e
ta
l 
d
e
liv
e
ry
 (
n
m
o
l 
m
in
-1
)
0
1
2
0
1
2
0
20
40
Fetal flow 
(fold change)
Ex
Maternal flow 
(fold change)
0
1
2
0
1
2
0
100
200
Fetal flow 
(fold change)
ExF
Maternal flow 
(fold change)
0
1
2
0
1
2
0
200
400
Fetal flow 
(fold change)
AcExF
Maternal flow 
(fold change)
20 
 
 
Fig. 10: Effect of amino acid input concentrations. Fetal venous-arterial difference for each amino acid group in 
response to varying the overall maternal and fetal amino acid arterial input concentrations simultaneously. Note the 
concentrations of all amino acid groups were varied by the same factor. 
 
3.8 Coordination of transporter activities 
The model parameters were fitted to determine which combination of transporter activities 
would provide the best overall fit of the fetal venous-arterial concentration differences from 
literature (7) (Table 3).  Compared to the reference simulations, fitting improved results 
especially for substrates that were initially under-predicted. AcEx was matched closely to the 
literature values (within 3.7%) and the low level of Ex was increased substantially. However, for 
AcExF and ExF the results deviated more from literature values than the original reference 
simulations. Compared to the reference parameters, the fitted transporter activities were 
adjusted by the following factors: accumulative ×0.75, exchange at MVM ×2.8, exchange at BM 
×59, and facilitative activity ×1.3. This very large increase in BM exchanger activity reflects the 
attempt by the algorithm to match amino acid Ex and its low sensitivity. 
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3.9 Elevated maternal phenylalanine level 
Finally, the model was used to explore the genetic condition of maternal phenylketonuria, where 
lack of phenylalanine hydroxylase causes an excess level of phenylalanine that can affect fetal 
development and function (37).  Phenylalanine is an exchange and facilitated transporter 
substrate. Therefore, net transfer of each amino acid group was modelled over a range of 
maternal ExF by including the additional phenylalanine. The results showed that elevated 
concentrations of ExF in the maternal compartment reduced the net transfer of all other amino 
acid groups (Fig. 11). Moreover, the model predicted negative net transfer of AcEx and Ex at high 
maternal phenylalanine concentrations, which implies that these amino acids were transported 
out of the fetal compartment.  
  
Fig. 11: Effects of elevated maternal phenylalanine concentrations in phenylketonuria for each amino acid group. 
Note ExF rises as it includes phenylalanine, but all other amino acids are severely reduced. Normal phenylalanine 
levels are around 39 µmol l
-1
, while for classic untreated phenylketonuria this exceeds 1200 µmol l
-1
 (37). For well 
managed pregnancies where maternal phenylalanine is kept within the UK target range of 100-250 µmol l
-1
 the 
model would still predict a significant reduction or even reversal in transfer of Ex, corresponding to threonine. 
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4. Discussion 
This study developed an integrated modelling approach to explain the interaction of transporters 
polarised to the microvillous apical and basal plasma membranes of the human placental 
syncytiotrophoblast. The modelling framework developed was effectively able to represent the 
complexity arising from the interactions between multiple species of amino acids and different 
types of transporters on both the MVM and BM. This will prove invaluable in determining the 
contribution of specific transporters to epithelial transport in the placenta and other transport 
systems. The ability to predict how specific transporters contribute to overall function will allow 
the design of targeted interventions in epithelial transport disorders. 
 The model first successfully described the fundamental transporter interactions at 
each of the placental plasma membranes separately, before these were combined for the 
system as a whole. The accumulative-exchange transporter configuration at the MVM allowed 
the accumulation of all the different types of amino acids into the syncytiotrophoblast. Indirect 
stimulation of amino acids that were not substrates of the accumulative transporter could be 
achieved by increasing the accumulative transporter activity to promote exchange. The 
syncytiotrophoblast uptake concentrations of both accumulative and exchange amino acid 
species were substantially higher than the maternal concentrations.  This accumulation against 
the concentration gradient is enabled by the energy required to maintain the constant sodium 
gradient whose electrochemical potential provides the driving force for the system. Similarly, the 
model confirmed that the facilitative-exchange transporter configuration at the BM was 
sufficient to ultimately transfer all amino acids to the fetus. In addition, indirect stimulation of 
amino acids that were not a substrate of the facilitative transporter was shown to be possible by 
increasing the facilitated transport activity to promote exchange across the BM. 
 When the overall transfer across the placenta was considered using physiological 
concentrations, the integrated model operated close to steady state (Fig. 4) and showed a 
favourable net transfer of all amino acid groups to the fetus (Table 3), in reasonable agreement 
with literature (7). This indicated that the model could provide a relatively robust representation 
of placental amino acid transfer, despite many simplifying assumptions. Fitting results suggested 
that the model predictions could be improved by changing the activities for each transporter. 
Though, it appeared difficult to adjust independently the concentration of certain amino acid 
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groups without affecting the transfer of others. In particular, improving the prediction for the 
exchange only substrate required a disproportional increase in BM exchanger activity (Table 3). 
 Simultaneous variation of the transporter activities revealed that multiple 
configurations could result in high transfer for certain amino acids (AcExF in Fig. 6). Amino acids 
groups that were substrates of the accumulative transporter (AcEx and AcExF) generally behaved 
in the same way when considered at the MVM, in contrast with those that were not 
accumulative transporter substrates (Ex and ExF, Fig. 7). Similarly, amino acid groups that were 
substrates of the facilitative transporter (ExF and AcExF) displayed the same response when 
observed at the BM, showing a distinctly different response compared with those that were not 
transported by the facilitative transporter (AcEx and Ex, Fig. 8). Against a background where 
strategies are being developed to specifically target placenta to deliver pharmacological or 
genetic therapies (38), modelling may allow more informed decisions as to which transporters to 
target. However, the differential effect on different amino acids by changing transporter activity 
should serve as a cautionary warning that potential unwanted side effects may be elicited by an 
intervention. 
 Simulation results were shown to be most sensitive to fetal, rather than maternal 
flow due to the low compartmental volume. However, compared to the physiological reference 
values, increasing flow further did not lead to significant changes in transfer (Fig. 9). Flow rates 
were only shown to be rate limiting when either maternal or fetal flow rates approached zero. 
Under the given conditions, substrates of the facilitative transporter displayed a positive 
relationship with flow, whereas the other amino acids showed the opposite behaviour. Maternal 
uterine and fetal umbilical blood flows are one of the few placental parameters that can 
currently be measured in vivo and this model may provide a basis for understanding their effect 
on the fetus. 
 It has to be emphasized that the current model was for the placenta and did not 
include maternal or fetal metabolism, which will alter amino acid availability in the maternal or 
fetal arteries. However, as demonstrated by the model, when overall maternal and fetal amino 
acid concentrations were varied, it was shown that placental transfer was increased by both high 
maternal and low fetal concentrations of amino acids, as would be expected. Nonetheless, 
placental transfer was mainly controlled by fetal concentrations, suggesting that amino acid 
transfer to the fetus is in part regulated by fetal demand. Furthermore, this means that 
increasing overall maternal amino acid concentrations above physiological levels is unlikely to be 
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an effective intervention strategy. However, interventions could also specifically target changing 
the relative amino acid composition which is important for exchanger function, as informed by 
the model. This is particularly relevant for inherited diseases of metabolism that affect the 
concentration of specific amino acids as shown by the model example of phenylketonuria, where 
maternal phenylalanine levels can be over 30× higher than normal (37), severely impairing 
placental transfer of other amino acids (Fig. 11). 
 It is important to consider the simplifying assumptions made in deriving the current 
model. In particular, amino acids were grouped according to their specificity for the various 
transporter types and each transporter type was modelled as a single representative transporter. 
In reality, numerous different individual transporters can be distinguished for each transporter 
type, each of which is specific to certain overlapping subsets of amino acids, with different 
substrate affinities (12). In addition, since the main focus was on the function of the transporters 
as a coordinated system, individual transporter models were kept relatively simple, in order to 
capture faithfully the underlying mechanisms for each type, while minimising the number of 
unknown parameters. For example, translocation and binding were assumed symmetric for the 
exchanger and facilitative transporter, however this is not an intrinsic limitation and given 
enough available data this assumption can be relaxed within the thermodynamic constraints for 
an energetically passive transport process (21, 23). For the active accumulative transporter the 
ultimate level of amino acid accumulation is determined by the sodium electrochemical 
potential difference, independent of the kinetics. The effect of membrane potential was included 
for sodium in the accumulative transporter, however an important limitation of the current 
model was that Eq. 4-6 only describe the transport of neutral amino acids. Therefore the amino 
acid groups considered in the present model should be subdivided further to specifically model 
the transport of charged amino acids by transporters such as system y+. In addition, placental 
metabolism was not considered in the model, as the main focus was on transport; this could 
potentially change the amount of amino acids available for transport and their relative 
composition. Another aspect not included in the model was transfer via paracellular routes, 
which are poorly understood anatomically (39). Paracellular diffusion will reduce the efficiency 
of the system because of high fetal amino acid concentrations, causing net diffusion in the fetal 
to maternal direction. All compartments in the model were assumed well-mixed, ignoring 
differences in local concentrations due to the maternal intervillous and fetal capillary flow. In 
addition, this implied that the intracellular concentrations in the syncytiotrophoblast were 
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assumed uniform, rather than forming a gradient. Including diffusion within the 
syncytiotrophoblast in the model did not affect results, as the estimated timescale for diffusion 
is fast compared to membrane transport in our model (T = h2/D = 0.1 s, with thickness h < 1×10-5 
m and diffusion coefficient D = 1×10-9 m2/s (40)). Nonetheless, further compartmentalisation 
within the syncytiotrophoblast could be important and this could lead to differences in the 
intracellular concentrations determining transport at the BM and MVM. 
 While the model was designed for amino acids, the transporters included in the 
model also transfer a wide range of other substances including xenobiotics. As such, the 
modelling framework can be widely applicable to transport functions both in the placenta and 
other transporting epithelia; for instance intestinal absorption of nutrients and drugs, 
reabsorption of nutrients from the renal tubules, and the transfer of nutrients and drugs across 
the blood brain barrier (41). 
In summary, a novel integrated modelling framework was developed for the placental 
amino acid transfer system as a whole. The model was shown to be able to capture successfully 
the principal features of the transfer system despite the necessary simplifying assumptions. 
Transporter modelling is currently limited by the availability of specific details about individual 
transporters, their kinetics and substrate specificity. However, one of the strengths of this 
modelling framework is that it can easily be updated as experimental data becomes available. To 
illustrate the potential of the model for representing clinical scenarios, the case of 
phenylketonuria was modelled; demonstrating how elevated maternal phenylalanine would 
restrict fetal delivery of all other amino acids. Ultimately it is hoped that this type of modelling 
approaches will inform biological understanding and aid the development of targeted 
intervention strategies. 
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